Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytotoxic CD8+ T lymphocytes (CTLs) are a critical component of the adaptive immune system responsible for recognizing and eliminating infected or malignant cells. They express CD8 and utilize their T-cell receptor (TCR) to bind antigens presented on MHC-I molecules. Upon activation, CTLs induce apoptosis in target cells through the release of cytotoxic granules (perforin and granzymes) or Fas/FasL interactions. Strategies for 'replacement' or rejuvenation of dysfunctional CTLs are being explored in cancer immunotherapy and chronic infections.
CTLs recognize and kill target cells expressing specific antigens via TCR interaction with MHC-I, releasing cytotoxic granules (perforin, granzymes) or activating Fas/FasL apoptotic pathways. They also secrete cytokines to enhance immune responses.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytotoxic CD8+ T Lymphocyte (CTL).